[1] |
Hong CD. Complementary and alternative medicine in Korea: current status and future prospects [J]. J Altern Complement Med, 2001, 7(Suppl 1): 33-40.
|
[2] |
Chen FP, Chen TJ, Kung YY, et al. Use frequency of traditional Chinese medicine in Taiwan [J]. BMC Health Serv Res, 2007, 7(1): 1-11.
|
[3] |
Eisenberg D, Davis R, Ettner S. Trends in alternative medicine use in the United States [J]. JAMA, 1997, 280(6): 370-371.
|
[4] |
Yamashita H, Tsukayama H, Sugishita C. Popularity of complementary and alternative medicine in Japan: a telephone survey [J]. Complement Ther Med, 2002, 10(2): 84-93.
|
[5] |
Debelle FD, Vanherweghem JL, Nortier JL. Aristolochic acid nephropathy: a worldwide problem [J]. Kidney Int, 2008, 74(2): 158-169.
|
[6] |
Ingsathit A, Thakkinstian A, Chaiprasert A, et al. Prevalence and risk factors of chronic kidney disease in the Thai adult population: Thai SEEK study [J]. Nephrol Dial Transplant, 2010, 25(5): 1567-1575.
|
[7] |
冯雪,方赛男,高雨鑫,等. 中药肾毒性国内外研究现状[J]. 中国中药杂志,2018, 43(3): 417-424.
|
[8] |
Lai MN, Lai JN, Chen PC, et al. Risks of kidney failure associated with consumption of herbal products containing Mu Tong or Fangchi: a population-based case-control study [J]. Am J Kidney Dis, 2010, 55(3): 507-518.
|
[9] |
关建红,翁维良. 对中药"毒性"与毒性分级的思考[J]. 中国中药杂志,2008, 33(4): 485-487.
|
[10] |
Loh AH, Cohen AH. Drug-induced kidney disease-pathology and current concepts [J]. Ann Acad Med Singapore, 2009, 38(3): 240-250.
|
[11] |
Inui KI, Masuda S, Saito H. Cellular and molecular aspects of drug transport in the kidney [J]. Kidney Int, 2000, 58(3): 944-958.
|
[12] |
张松波,周宏灏. 药物代谢性别差异及与核受体的关系[J]. 中国药理学通报,2007, 23(3): 292-294.
|
[13] |
Schlender JF, Vozmediano V, Golden AG, et al. Current strategies to streamline pharmacotherapy for older adults [J]. Eur J Pharm Sci, 2017, 111: 432-442.
|
[14] |
时琳,薛颖. 含毒性成分中成药的应用探讨[J]. 中成药,2015, 37(7): 1626-1629.
|
[15] |
阳长明. 乌头碱类成分中药制剂质量控制探讨[J]. 药品评价,2011, 8(10): 23-27.
|
[16] |
李娆娆,张志杰,王祝举,等. 近60年中药毒副作用及不良反应文献分析[J]. 中国实验方剂学杂志,2010, 16(15): 213-216,221.
|